• AlzeCure received the full USD 10 million upfront payment from Eli Lilly under the Alzstatin collaboration and licensing agreement.
• Closing conditions were met, completing the initial transaction for Alzstatin, including drug candidate ACD680.
• Lilly takes global rights to Alzstatin, covering further clinical development, regulatory work, and commercialization.
• Deal terms include development and commercial milestones, mid-single-digit royalties, total value over USD 1 billion excluding royalties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AlzeCure Pharma AB published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.